{"filing":{"accession_number":"0001193125-26-352126","cik":"0001645460","ticker":"CUE","company_name":"Cue Biopharma, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"cue-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-20260814.htm"},"events":[{"id":27855,"run_id":25430,"accession_number":"0001193125-26-352126","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Cue Biopharma's second quarter 2026 financial results, including revenue of $7.9 million, R\u0026D expenses of $49.0 million, and a net loss of $153.1 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated financial statements and detailed discussion of quarterly operating results.","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29559,"accession_number":"0001193125-26-352126","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Cue Biopharma's second quarter 2026 financial results, including revenue of $7.9 million, R\u0026D expenses of $49.0 million, and a net loss of $153.1 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated financial statements and detailed discussion of quarterly operating results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:04:59.326154+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29559,"accession_number":"0001193125-26-352126","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Cue Biopharma's second quarter 2026 financial results, including revenue of $7.9 million, R\u0026D expenses of $49.0 million, and a net loss of $153.1 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated financial statements and detailed discussion of quarterly operating results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:04:59.326154+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-08-14"}]}